Siegfried Holding AG

Swiss Stock Exchange:SFZN.SW

Sector

🏥 Health Care

Industries

🔬 Clinical Trials

🧬 Biotechnology

🔬 Chemicals & Advanced Materials

🌿 Fertilizers

💊 Pharmaceuticals

Location

Switzerland

Market Cap

USD 5.05 B

Share Price

USD 115.48

Avg Daily Volume

90,504

Change (1 day)

0.37%

Change (1 year)

-89.04%

Change (YTD)

-89.41%

Siegfried Holding AG EPS (Diluted) for the year ending December 31, 2024: USD 40.61

Siegfried Holding AG EPS (Diluted) is USD 40.61 for the year ending December 31, 2024, a 30.39% change year over year. EPS (Diluted) reflects the company's earnings per share adjusted for the potential dilution that could occur if all convertible securities were converted to common stock, providing a more conservative profitability measure.

Siegfried Holding AG EPS (Diluted) for the year ending December 31, 2023 was USD 31.14, a -20.62% change year over year.
Siegfried Holding AG EPS (Diluted) for the year ending December 31, 2022 was USD 39.23, a 62.48% change year over year.
Siegfried Holding AG EPS (Diluted) for the year ending December 31, 2021 was USD 24.15, a 50.75% change year over year.
Siegfried Holding AG EPS (Diluted) for the year ending December 31, 2020 was USD 16.02, a 23.84% change year over year.

Quarterly
Annual
TTM

From:

To:

Zoom:

Key data

Date	EPS (Diluted)	Shares (Diluted, Weighted)	Selling, General, and Administrative Expenses (SG&A)	Research and Development (R&D) Expenses

Swiss Stock Exchange: SFZN.SW

Siegfried Holding AG

CEO	Mr. Marcel Imwinkelried
IPO Date	April 14, 1995
Location	Switzerland
Headquarters	Untere Bruehlstrasse 4
Employees	3,886
Sector	🏥 Health Care
Industries Clinical Trials 🧬 Biotechnology 🔬 Chemicals & Advanced Materials 🌿 Fertilizers 💊 Pharmaceuticals

Description

Siegfried Holding AG engages in the life sciences business worldwide. The company develops and produces active pharmaceutical ingredients (APIs) and intermediates, as well as finished dosage forms, including solid oral dosage forms, and sterile and aseptic filling injectables, ophthalmics, and inhalative products. It offers contract development and manufacturing services, including pharmaceutical and analytical development, process and analytical transfer, commercial manufacturing and packaging, and scale up and clinical trial material production. In addition, the company provides APIs and controlled substances focusing on anesthetics, pain treatment applications, and central nervous and respiratory diseases. Further, it licenses oral solid and sterile products; assembles registration dossiers; and offers a common technical document for various products. The company was founded in 1873 and is headquartered in Zofingen, Switzerland.